Header updated on 24th April 2008

Market has been looking for an announcement re a licensing deal for Cetilistat, the obesity drug; instead it has been hit with the withdrawal of Renzapride, colonitis drug, following an unauspicious performance at Phase III. Folloiwng has been edited to reflect the situation

Alizyme is a speciality biopharmaceutical company that has been developing product categories for inflammatory gastrointestinal disorders, obesity and supportive cancer care . It is currently trading at a five year low of around 27p with a market cap. of around 60m. Prudential owned a near 20% stake (reduced in sale today?) There was good institutional taku-up of a placing in March rasing 10m at 50p; no wonder there has been "angry" selling. The directors hold 3.34million shares or about 1.7% of the equity (of which Tim McCarthy, CEO has 1.1million); thus, after some 10 years of development effort, they must be comletely focused on the success of the company and multiplying the value of their holdings (but with real doubts about their marketing competence). Alizyme had previously raised capital sums in the past three years at around 70p and 100p so it was somewhat surprising to see the share fall through its 70p support level. Clearly one reason is the current disaffection with the biopharm. market. Another has to be disappointment for the failure of the CEO, Tim McCarthy, to deliver on his expectation that 2007 would be a transformative year. The key question is whether 2008 will be that year and when is it likely to happen? The following points are relevant:

1. Alizyme did sign one deal in late-2007: with Prometheus Labs (U.S.) for the Colal-Pred, at a potential market of $250m, the smallest potential of their four products. Prometheus pay $2.5m up-front with a total of $15m payable upon future development milestones. They are responsible for all US development costs and will pay Alizyme undisclosed royalty rates which will increase with net sales. The deal was followed by a Japanese licensing agreement (which also gave Alizymen access to additional potential drug candidates).

2. This perhaps sets a precedent for subsequent deals for their other products. Cetistat (obesity) has an estimated potential of $1 billion p.a. sales and ATL-104 (mucositis) has a potential of $500m sales. The U.S. FDA has encouraged AZM to also launch a Phase III exercise for Cetistat for all diabetes sufferer because of positive II results for diabetes sufferers who also suffer from obesity.

3. Whilst the development programmes for the other drugs are on-going and appear to be satisfactorily funded from present resources, this is not the case for Cetilistat. The "Product and Company Update statement" (7th Jan 2008) says that 'the Phase III development programme is now ready to commence following the conclusion of a commercial deal'. So, perhaps for the first time, the development programme would be delayed if there was not a funding deal in either the U.S. or Europe. The reason for the sp shooting to nearly 200p in 2004 was the signing of a deal with Takada of Japan for some $50M development funding.

In response to a question at the Conference to report the Renzapride fiasco, McCarthy seemed pleased that there were six potential bidders for Cetilistat; however, that implies any announcement is some time away. When it comes, however, taking a line from the Takada and Prometheus deals it would seem likely that there would be of the order of $100m funding to support development. Of course, the major cash flow will be from licensing of actual sales. The analysts do their own discounted cash flow exercises; those seen tend to dwarf current valuations of the company.

There is not a strong argument for jumping in unless and until the sp establishes a baseline. Given the peaks in the sp, the time will probably come when there will be a very significant jump. An alternative scenario, is that management continue to rpove their level of incompetence and a buy-our results. Clearly the strength of the company is in their biochemists.

Eric

Investor's Chronicle
19th July 2007
Writer: Shunil Roy-Chaudhuri

ALIZYME CONFIDENT OF CUTTING DEALS

"It's long been a case of jam tomorrow with Alizyme, but chief executive Tim McCarthy's comments suggest that it may now be time to start buttering the toast. Mr McCarthy says he's expecting to enter deals in 2007, although he wouldn't say on what drugs, or how many deals are in the pipeline.

Even so, he said Alizyme is holding discussions on all four of its products and that there's the possibility of deals on any one of them, or even of multiple deals for each product, while the group could also secure separate contracts for different regions (such as the US or Europe).

No new deals were cut in this first half, though, so there was no turnover to record. But progress is being made on drug development, with cetilistat (for the treatment of obesity and diabetes) given the go-ahead for Phase III clinical trials from the US Food and Drug Administration. Meanwhile, Alizyme is also progressing with the Phase III US trial for renzapride (which treats irritable bowel syndrome).

The group has plenty of cash to fund further programmes, but Mr McCarthy says that in 2008 the group won't face the high costs incurred on its 2007 Phase III trials".

TIP UPDATE:

"Buy"

"Any further deals could be value-transforming for Alizyme. So, for those with the stomach for risk, the shares remain worth buying".


ALIZYME (AZM)
ORD PRICE: 97p MARKET VALUE: 194m
TOUCH: 97-98p 12-MONTH HIGH: 128p LOW: 71p
DIVIDEND YIELD: nil PE RATIO: NA
NET ASSET VALUE: 9p NET CASH: 19m

Thanks for that LC good news on a red day always welcome.

MACD to cross over - I hope to see 95 - 1 short term this is too cheap at the moment

Yes Nar1 there are a good few of us waiting patiently with this one. The potential has been well covered on this thread with valid views both for and against. We now hopefully await a bullish company announcement. sp 82p

Nice little write-up in Shares Mag today in a similar vein.

Yeah I think anybody whose been following this stock knows its a good price to buy. We all know the potential but we will just have to sit and wait.. Queen could you post what shares mag wrote if possible..

Alizyme has been looking for a partner to develop its anti-obesity product Cetilistat since it completed Phase II trials in August 2008. Hopes have been raised that it could soon be on the cards by Chairman Brian Richards comments at its interim results in July that it expects to conclude a number of transforming deals, this year. The course of Phase III trials has already been agreed with US regulators the FDA and future sales of the product are forecast to tip $1 billion a year, so when a deal comes it could be huge. There is always an element of risk with drug discovery companies but Alizyme has a good chance of securing a lucrative deal which would send its shares soaring. Numis analyst Brett Pollard has a 150p target price for the shares some 78% above their current level. (ST) I say its a --- BUY ---

Sorry Nar1, you beat me to it!

there was lots of hope at the beginning of the year, that this was going TO BE THE YEAR. Anyone still hold any hope this will be the year????

Yes, imo i'm sure deals are just around the corner.........but you never know.
I have to say holding this share has been great fun! not for the faint of heart.

Kivver, as far as I know there has been nothing to indicate that the situation has changed from what we already understand. At 84p the sp, although 7p overall under my cost price per share is more a reflection how the market has been of late. Many institutions and private investors have been seeking safer havens in bonds or larger good cash flow company shares, which is understandable. However, if as is hoped patient investors hear good news on developments, the sp should rebase at a higher level. I still live in hope.

looks like Prudential has been buying further stock and now holds over 14%

Hi Guscavalier - I noticed the Prudential buy, too. The shares are almost at their lowest point for a year, and I keep thinking they will turn. I sold sometime ago, at a good profit (luckily!) but am looking for the right time to come back in.

The Chairman's statement on 19 July, and various webcasts, have included: "We are in discussions relating to all four of our products and will explore innovative deals designed to retain the maximum value for shareholders . . . We remain confident that in 2007, we will conclude a number of transforming deals for Alizyme."

I guess even just one 'transforming deal' would do the trick and I do believe they can do it.

Toya- I agree with you. We still wait for an announcement. At least it is good training for if ever you want to watch paint dry! I would be disappointed if we do not hear positive news before year end and the sp has reflected the lack of news. I think if you feel positive, it does not really matter if you cannot time purchases to perfection, as this rarely happens. Good Luck.

well its looks like another year is going to pass without an announcementor have we got a bit carried away somewhere???? Lots of excitement at the bigining of the year that this 'would be THE year', oh well next year? (probably somewhere in the next 10 years!)

Have you noticed AZM moving upwards this morning? Climbed 6.77% to 76.5-77.25. Could be an announcement coming soon?? No news as yet, as far as I can see.

hi toya, unfortunately we've heard it a hundred times before. good luck if your in.

Thanks Kivver - I've made money on AZM earlier in the year (when it topped 100p) but am currently waiting for the right moment to come back in. It should make that price again before the year is out I reckon.

This is a bit better!Alizyme PLC
10 October 2007



For Immediate Release 10 October 2007



ALIZYME PLC

Phase III Clinical Product Development Update

Renzapride and COLAL-PRED(R)


Cambridge UK, 8 October 2007: Alizyme plc (LSE: AZM) announces an update on its
Phase III clinical product development.


Renzapride

Completion of patient recruitment into first Phase III pivotal efficacy study

Headline results expected in April 2008

Special Protocol Assessment agreed with FDA for second Phase III pivotal
efficacy study


We are pleased to announce the completion of patient recruitment into the first
Phase III pivotal efficacy study of renzapride in constipation-predominant
irritable bowel syndrome (IBS-C).

The study (Study 038), a multi-centre, randomised, double-blind,
placebo-controlled, parallel group, pivotal efficacy study, has recruited over
1,800 female patients with IBS-C. Patients are treated for a 12-week period. The
primary endpoint is patients' self assessment of relief of their overall IBS
symptoms. Secondary endpoints include adequate relief of abdominal pain/
discomfort and of bowel problems. Headline trial results are expected to be
reported in April 2008.

At the end of the 12-week treatment period in Study 038, patients can elect to
continue into an open label extension study (Study 052) to evaluate the
long-term safety and tolerability of renzapride taken for 12 months. Patients
continue to be recruited into this study with results expected to be reported in
Q2 2009.

We are also pleased to announce that agreement has been reached with FDA on the
clinical protocol for the second Phase III pivotal efficacy study (Study 109) of
renzapride in IBS-C under the Special Protocol Assessment ('SPA') procedure.
Recruitment into Study 109 is expected to commence in 2008.


COLAL-PRED(R)

Patient recruitment on track in EU Phase III clinical trial and due to
complete by end of 2007

Headline results expected in Q2 2008


Recruitment into our EU Phase III registration clinical trial in up to 750
patients with active moderate to severe ulcerative colitis remains on target for
completion in 2007. Subject to the recruitment being completed this year,
headline results are expected to be reported in Q2 2008.

Successful results from the EU Phase III trial would allow a Marketing
Authorisation Application (MAA) to be submitted for the EU in H2 2008.


Commenting, Tim McCarthy, Chief Executive Officer said:

'We are delighted to have closed recruitment for this key pivotal study with
renzapride. The headline results, expected in April 2008, will mark the
completion of the first Phase III clinical trial of renzapride and are expected
to confirm its product profile and competitive position. We anticipate
commencement of a second Phase III study in 2008, which has now been agreed with
FDA under the SPA procedure.

The first half of 2008 will see significant clinical news flow from the
renzapride and COLAL-PRED(R) Phase III clinical trials and emphasises the late
stage nature of our product portfolio.

In addition, I continue to be pleased with the ongoing discussions with
potential partners for the further development and commercialisation of our
products and remain confident of successfully concluding a number of deals
across the portfolio this year.'


For further information, please contact:

Tim McCarthy, Chief Executive Officer
David Campbell, Finance Director
ALIZYME plc +44 (0) 1223 896000

Lisa Baderoon/Rebecca Skye Dietrich
BUCHANAN COMMUNICATIONS +44 (0) 20 7466 5000


Further information on Alizyme can be found on the Company's website:

www.alizyme.com




Editor's Note


Alizyme plc

Alizyme is a speciality biopharmaceutical development company, focused on the
therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer
supportive care. It is developing cetilistat for the treatment and management of
obesity and related diseases, such as Type II diabetes, renzapride for the
treatment of irritable bowel syndrome ('IBS'), COLAL-PRED(R) for ulcerative
colitis, and ATL-104 for mucositis, a side effect of cancer therapy.


Special Protocol Assessment (SPA)

In conjunction with the reauthorisation of the Prescription Drug User Fee Act of
1992 (PDUFA) in November 1997, FDA agreed to specific performance goals for
special protocol assessment and agreement. These goals provide that, upon
request, FDA will evaluate certain protocols (i.e. carcinogenicity protocols,
stability protocols, and Phase III protocols for clinical trials that will form
the primary basis of an efficacy claim) to assess whether they are adequate to
meet scientific and regulatory requirements.

Once FDA and the sponsor concur, under the Special Protocol Assessment, the
Agency documents agreement that the design and planned analysis of a study
adequately address objectives in support of a regulatory submission.

As stated in the PDUFA goals for Special Protocol Assessment and agreement,
having agreed to the design, execution, and analyses proposed in protocols
reviewed under this process, the Agency will not later alter its perspective on
the issues of design, execution, or analyses unless public health concerns
unrecognized at the time of protocol assessment under this process are evident.


Cetilistat

Alizyme's metabolic product, cetilistat, is being developed for the treatment of
obesity and associated conditions. It is a gastrointestinal lipase inhibitor
that blocks fat digestion and absorption, leading to reduced energy intake, and
thus weight loss. It is distinct from most other anti-obesity agents as it does
not act on the brain to reduce appetite, but acts peripherally. The compound
remains in the gastrointestinal tract with no significant absorption into the
body. It can, therefore, be expected to have a superior risk-benefit profile to
centrally acting drugs. Accordingly, cetilistat is not subject to the safety
concerns generally associated with centrally acting drugs.

Cetilistat has completed an extensive Phase II development programme achieving
both statistically significant weight loss and statistically significant
reduction in diabetes marker HbA1c. Following successful end of Phase II
discussions with the US FDA in 2006, outline plans for the Phase III clinical
development programme, comprising three studies involving obese patients and
obese patients with Type II diabetes or other associated co-morbidities, were
agreed. The protocol for the first pivotal Phase III clinical trial was approved
by FDA in April 2007 under SPA.

Roche's Xenical(R) is an approved obesity product and is also a peripherally
acting lipase inhibitor. However, in clinical trials, cetilistat has been
demonstrated to be much better tolerated than Xenical(R) which has side effects
that detrimentally affect patient compliance.


Renzapride

Alizyme's gastrointestinal product, renzapride, is being developed for the
treatment of constipation-predominant IBS ('IBS-C') and for mixed-symptom IBS ('
IBS-M'). It aims to be a more effective treatment for IBS-C than is currently
available and also to become the first line treatment for IBS-M. IBS is a
functional gastrointestinal disorder characterised by recurrent symptoms of
abdominal pain and discomfort associated with disturbed bowel function, which
may also be accompanied by a feeling of bloating. Patients may have IBS-C, IBS-M
or diarrhoea-predominant IBS ('IBS-D').

There are currently few effective drug treatments available for IBS. IBS is one
of the most frequent disorders seen by physicians with estimates of up to 22% of
the general population experiencing symptoms of IBS at some time, of whom around
35% have IBS-C and around 40% have IBS-M, both of which renzapride aims to
address. The remainder of around 25% have IBS-D.

Renzapride is both a 5-HT4 receptor full agonist (which acts as a pro-kinetic,
enhancing motility) and a 5-HT3 receptor antagonist (which acts to reduce GI
motility, thus helping to reduce diarrhoea, abdominal pain and discomfort). This
dual mode of action is unique and gives renzapride the potential to normalise
bowel function rather than move from one extreme of constipation or diarrhoea to
the other. It may, therefore, provide benefit in both IBS-C and IBS-M, covering
up to 75% of the IBS patient population.

Renzapride has the opportunity to be the market leader as it has been shown in
Phase II studies to have the potential to be more effective than Novartis'
Zelnorm(R), which is not approved for use in the EU and has currently been
suspended from sale in the US and other countries. Prior to its suspension,
Zelnorm(R) achieved annual sales of $561 million for 2006. This, therefore,
represents a significant commercial opportunity for renzapride.


COLAL-PRED(R)

COLAL-PRED(R) is a proprietary gastrointestinal product developed by Alizyme for
the treatment of ulcerative colitis ('UC'). UC is an inflammatory disease of the
colon, which causes symptoms such as abdominal pain, bleeding, cramping, fatigue
and diarrhoea. These conditions are characterised by episodes of acute flare of
the inflammation, followed by periods of remission. In severe cases, surgery may
be required to remove the diseased tissue. Currently around 1 million people in
major territories suffer from UC. This market is dominated by anti-inflammatory
steroids and 5-ASA products, which have safety and/or efficacy issues.

COLAL-PRED(R) is the combination of Alizyme's proprietary colonic drug delivery
system, COLAL(R), and prednisolone sodium metasulphobenzoate, an approved
steroid in Europe. COLAL-PRED(R) has a starch coating that is only broken down
in the gut by bacteria occurring in the colon. This leads to topical delivery of
prednisolone to the colon rather than systemic delivery. It has been shown in a
Phase II clinical trial to provide levels of efficacy comparable to that
reported for prednisolone, but without the side effects of steroids.


ATL-104

ATL-104 is being developed by Alizyme as an orally administered mouthwash for
the treatment of mucositis of the mouth and gastrointestinal tract arising
during cancer treatment. This provides ease and convenience of administration
and enables local delivery of treatment for oral and gastrointestinal mucositis
with no significant absorption into the body.

ATL-104 has successfully completed a Phase IIa 'proof of concept' clinical trial
in patients with lymphoma and myeloma. ATL-104 is currently being assessed for
the optimum route for further development through discussion with FDA, EMEA and
our advisors.

Globally there are over 4 million new cases of cancer each year. Oral mucositis
occurs in 40% of all cancer patients. In bone marrow transplant patients, over
70% of patients suffer from mucositis, and in head and neck cancer treatments,
mucositis occurs in up to 80% of patients. Mucositis is characterised by severe
ulceration, bleeding and pain in the mouth and gastrointestinal tract, caused by
damage to the cells that line these tissues by cancer chemotherapy and
radiotherapy. These symptoms can be very painful, requiring the administration
of opiates, can reduce the ability of the patient to receive nutrition orally,
can be a source of infection and can be potentially life threatening.

The identification of compounds for successful research, their progress through
development and the obtaining of regulatory approvals or authorisations before
marketing, manufacture and/or distribution of products is not certain or a
formality.


This information is provided by RNS
The company news service from the London Stock Exchange

Alizyme PLC
16 October 2007


For Immediate Release 16 October 2007


ALIZYME PLC


TR - 1: NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attached:

Alizyme plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation:

ABN AMRO BANK N.V. London Branch

4. Full name of shareholder(s) (if different from 3.)

5. Date of the transaction and date on which the threshold is crossed or
reached:

12/10/2007

6. Date on which issuer notified:

15/10/2007

7. Threshold(s) that is/are crossed or reached:

3%

8. Notified details:

A: Voting rights attached to shares

Class/type of Situation previous to Resulting situation after the triggering transaction
shares the Triggering
transaction
if possible
using the ISIN Number of Number of Number of Number of voting % of voting
CODE Shares Voting shares rights rights
Rights Direct Direct Indirect Direct Indirect
Ordinary
Shares 7,900,000 7,900,000 8,400,000 8,400,000 4.19%
GB 2p
GB0000374289

B: Financial Instruments

Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting rights that may % of
financial date Conversion be acquired if the instrument is voting
instrument Period/ exercised/ converted. rights
Date

Total (A+B)

Number of voting rights % of voting rights
8,400,000 4.19%

9. Chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held, if applicable

Proxy Voting:

10. Name of the proxy holder:

n/a

11. Number of voting rights proxy holder will cease to hold:

n/a

12. Date on which proxy holder will cease to hold voting rights:

n/a

13. Additional information


14. Contact name:

David Campbell, Finance Director

15. Contact telephone number:

+ 44 (0) 1223 896000

For further information, please contact:

David Campbell, Finance Director
ALIZYME plc Tel No: + 44 (0) 1223 896000

Further information on Alizyme can be found on the Company's website:

www.alizyme.com